{"Clinical Trial ID": "NCT00499083", "Intervention": ["INTERVENTION 1:", "Vaccine", "Patients with negative HER-2/neu tumours received therapeutic autologous dendritic cells: injected into the primary breast mass or a palpable axillary node, one week after the first, second and third T treatments.", "\u2022 Adjuvant hormone therapy for patients with tumours with estrogen receptors and/or progesterone. Premenopausal patients will be treated with tamoxifen. Post- and post-menopausal women may receive tamoxifen or an aromatase inhibitor.", "Patients received 4 cycles of paclitaxel: 175 mg/m2 (IV), followed by 4 cycles of cyclophosphamide: 600 mg/m2 IV and doxorubicin hydrochloride: 60 mg/m2 IV at dense biweekly doses", "All patients had pre-treatment biopsy and secondary tumour biopsy after 4 cycles of paclitaxel to evaluate responses to dendritic cell injections."], "Eligibility": ["CHARACTERISTICS OF DISEASE:", "Invasive breast cancer confirmed histologically meets the following criteria:", "Primary tumour 3 cm by mammography, ultrasound or palpation AND/or palpable axillary lymph nodes > 1 cm", "- Survivin and/or IHC positive carcinoembryonic antigen", "The tumours must be located by examination or ultrasound to allow the injection of tumours.", "No stage IV or metastatic disease", "- HER2/Neu-Neu-Neu-Neu-Neu-Neu by IHC", "If 2+ or in the undetermined range, additional tests of superexpression HER2/neu by fluorescent in situ hybridization (FISH) are required.", "Known situation of hormone receptors", "CHARACTERISTICS OF PATIENTS:", "Women", "Pre-, peri- or post-menopausal", "ECOG Performance Status 0-1", "No pregnancy or breast-feeding", "Negative pregnancy test", "Fertile patients should use effective contraception during and up to 6 months after completion of treatment with the study.", "ANC 1,500/mm3", "Number of platelets 100 000/mm3", "- Alcaline phosphatase 1.5 times the upper limit of normal (ULN)", "Total bilirubin 1.5 times ULN", "AST and ALT 1.5 times ULN", "Creatinine < 1.5 times ULN", "No serious active infection", "No prior malignancy, except for skin cancer of sufficiently treated basal or squamous cells, non-invasive carcinoma or other cancer whose patient has not been affected for 5 years.", "No co-morbidity or condition that would interfere with the evaluation and procedures of the study or prevent participation in the study", "THERAPE PRIOR CONCURENT:", "No prior chemotherapy or radiation therapy"], "Results": ["Performance measures:", "Number of patients with a complete pathological response", "- Appreciated by the institutional pathologist.", "Grade 1: Discontinuation of all tumours during microscopic evaluation in breast and NL", "Grade 2: presence of in situ carcinoma only in the breast, no invasive tumours, and no tumours found in NL", "Grade 3: presence of invasive carcinoma with stromal alteration, such as sclerosis or fibrosis", "Grade 4: No or little changes in tumour appearance", "Delay: During a definitive surgical procedure.", "Results 1:", "Title of the arm/group: Vaccine", "Description of the arm/group: Patients with negative HER-2/neu tumours received therapeutic autological dendritic cells: injected into the primary breast mass or a palpable axillary node, one week after the first, second and third T treatments.", "\u2022 Adjuvant hormone therapy for patients with tumours with estrogen receptors and/or progesterone. Premenopausal patients will be treated with tamoxifen. Post- and post-menopausal women may receive tamoxifen or an aromatase inhibitor.", "Patients received 4 cycles of paclitaxel: 175 mg/m2 (IV), followed by 4 cycles of cyclophosphamide: 600 mg/m2 IV and doxorubicin hydrochloride: 60 mg/m2 IV at dense biweekly doses", "All patients had pre-treatment biopsy and secondary tumour biopsy after 4 cycles of paclitaxel to evaluate responses to dendritic cell injections.", "Total number of participants analysed: 14", "Type of measurement: Number", "Unit of measurement: participants 2"], "Adverse Events": ["Undesirable Events 1:", "Total: 1/3 (33.33 per cent)", "Febrile neutropenia 1/3 (33.33%)"]}